September 2, 2024 01:00 AM EDTUpdated September 3, 06:44 AM

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Max Bayer

Pharma Reporter

The potential of Sanofi’s closely-watched BTK inhibitor in multiple sclerosis is coming into clearer view amid plans to narrow the focus of the French company’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Bristol Myers touts LAG-3 strategy in lung cancer as it preps for showdown with Merck’s Keytruda

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

Sanofi’s BTK in­hibitor goes 1-for-3 in key MS tri­als, slows dis­abil­i­ty pro­gres­sion

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression